Olema Pharmaceuticals, Inc.
OLMA
$13.59
-$0.23-1.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.53% | 15.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.78% | 9.17% | |||
| Operating Income | -15.78% | -9.17% | |||
| Income Before Tax | -15.26% | -9.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.26% | -9.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.26% | -9.11% | |||
| EBIT | -15.78% | -9.17% | |||
| EBITDA | -15.97% | -8.86% | |||
| EPS Basic | -2.38% | -2.44% | |||
| Normalized Basic EPS | -2.38% | -2.44% | |||
| EPS Diluted | -2.38% | -2.44% | |||
| Normalized Diluted EPS | -2.38% | -2.44% | |||
| Average Basic Shares Outstanding | 12.57% | 6.51% | |||
| Average Diluted Shares Outstanding | 12.57% | 6.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||